MRM 0.00% $2.69 mma offshore limited

Any views on the impairment reversals of $47m in the 2023 year...

  1. 32 Posts.
    Any views on the impairment reversals of $47m in the 2023 year and $35m in the 2022 year and equate to a significant part of earnings.

    Obviously these benefit EBIT, which I note is what management is assessed on for STI, predominantly, and feeds into improved EPS.

 
watchlist Created with Sketch. Add MRM (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.